Polydeoxyribonucleotide in the Treatment of Tendon Disorders, from Basic Science to Clinical Practice: A Systematic Review.
Davide BizzocaGiovanni BrunettiLorenzo MorettiAndrea PiazzollaGiovanni VicentiFrancesco Luca MorettiGiuseppe SolarinoBiagio MorettiPublished in: International journal of molecular sciences (2023)
Polydeoxyribonucleotide (PDRN) is a proprietary and registered drug with several beneficial effects, including tissue repairing, anti-ischemic action, and anti-inflammatory properties. The present study aims to summarize the current evidence about PRDN's clinical effectiveness in the management of tendon disorders. From January 2015 to November 2022, OVID-MEDLINE ® , EMBASE, Cochrane Library, SCOPUS, Web of Science, Google Scholar and PubMed were searched to identify relevant studies. The methodological quality of the studies was evaluated, and relevant data were extracted. Nine studies (two in vivo studies and seven clinical studies) were finally included in this systematic review. Overall, 169 patients (male: 103) were included in the present study. The effectiveness and safeness of PDRN has been investigated in the management of the following diseases: plantar fasciitis; epicondylitis; Achilles tendinopathy; pes anserine bursitis; chronic rotator cuff disease. No adverse effects have been recorded in the included studies and all the patients showed an improvement in clinical symptoms during the follow-up. PDRN are a valid emerging therapeutic drug in the treatment of tendinopathies. Further multicentric randomized clinical studies are needed to better define the therapeutic role of PDRN, especially in combined clinical protocols.
Keyphrases
- systematic review
- rotator cuff
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- randomized controlled trial
- clinical practice
- public health
- anti inflammatory
- peritoneal dialysis
- prognostic factors
- open label
- patient reported outcomes
- double blind
- drug induced
- meta analyses
- adverse drug
- single molecule
- quality improvement